Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Risks and benefits of bisphosphonates. Br. J. Cancer98(11), 1736–1740 (2008).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev.27(3), 165–176 (2001).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res.12(20 Pt 2), 6243s–6249s (2006).
   PubMed Web of Science ®Google Scholar
• Martin J, Coleman R, Mundy G. VI Meeting on Cancer-Induced Bone Disease. Expert Rev. Anticancer Ther.7(4), 461–464 (2007).
   PubMedGoogle Scholar
• Coleman RE. The role of bisphosphonates in breast cancer. Breast13(Suppl. 1), S19–S28 (2004).
   Google Scholar
• Coleman RE, Guise TA, Lipton A et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin. Cancer Res.14(20), 6387–6395 (2008).
   PubMedGoogle Scholar
• Body J-J, Mancini I. Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev. Anticancer Ther.3(2), 241–246 (2003).
   PubMedGoogle Scholar
• Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia10(2), 169–180 (2005).
   PubMed Web of Science ®Google Scholar
• Briest S, Wolff AC. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Rev. Anticancer Ther.7(9), 1243–1253 (2007).
   PubMed Web of Science ®Google Scholar
• Baud’huin M, Duplomb L, Velasco CR, Fortun Y, Heymann D, Padrines M. Key roles of the OPG–RANK–RANKL system in bone oncology. Expert Rev. Anticancer Ther.7(2), 221–232 (2007).
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Grimaldi A, Di Bella S et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res.23(3), 373–379 (2008).
   PubMedGoogle Scholar
• Perifanis V, Vyzantiadis T, Tziomalos K et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassaemia. Ann. Hematol.86(1), 23–30 (2007).
   PubMed Web of Science ®Google Scholar
• Martini G, Gennari L, Merlotti D et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone. Bone40(2), 457–463 (2007).
   PubMed Web of Science ®Google Scholar
• Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos. Int.17(5), 693–703 (2006).
   PubMed Web of Science ®Google Scholar
• Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol.19(8), 1407–1416 (2008).
   PubMed Web of Science ®Google Scholar
• Krempien R, Niethammer A, Harms W, Debus J. Bisphosphonates and bone metastases: current status and future directions. Expert Rev. Anticancer Ther.5(2), 295–305 (2005).
   PubMed Web of Science ®Google Scholar
• Saad F, Adachi JD, Brown JP et al. Cancer treatment-induced bone loss in breast and prostate cancer. J. Clin. Oncol.26(33), 5465–5476 (2008).
   PubMed Web of Science ®Google Scholar
• Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev. Anticancer Ther.8(9), 1377–1385 (2008).
   PubMed Web of Science ®Google Scholar
• Edwards BJ, Gounder M, McKoy JM et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol.9(12), 1166–1172 (2008).
   PubMed Web of Science ®Google Scholar
• Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J. Natl Cancer Inst.99(13), 1016–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg.61(9), 1115–1117 (2003).
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22(10), 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.102(4), 433–441 (2006).
   PubMed Web of Science ®Google Scholar
• Bagan JV, Jimenez Y, Diaz JM et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol.45(7), 645–656 (2009).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Biphosphonate related osteonecrosis of the jaws: risk factors in breast cancer patients. A case control study. J. Clin. Oncol.26(28), 4634–4638 (2008).
   PubMedGoogle Scholar
• Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck31(2), 202–206 (2008).
   Google Scholar
• Walter C, Al-Nawas B, Grotz KA et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol.54(5), 1066–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol.23(34), 8580–8587 (2005).
   PubMed Web of Science ®Google Scholar
• Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg.65(7), 1328–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br. J. Haematol.134(6), 620–623 (2006).
   PubMed Web of Science ®Google Scholar
• Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grotz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer115(8), 1631–1637 (2009).
   PubMed Web of Science ®Google Scholar
• Vahtsevanos K, Kyrgidis A, Verrou E et al. Bisphosphonate related osteonecrosis of the jaws: a longitudinal cohort study of risk factors in cancer patients. J. Clin. Oncol. DOI: 10.1200/JCO.2009.21.9584 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Raje N, Woo SB, Hande K et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin. Cancer Res.14(8), 2387–2395 (2008).
   PubMedGoogle Scholar
• Kyrgidis A, Andreadis C. Clinical characterization might help in preventing osteonecrosis of the jaw. Clin. Cancer Res.14(24), 8321 (2008).
   PubMedGoogle Scholar
• Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Bioscience Hypotheses2, 34–36 (2009).
   Google Scholar
• Landesberg R, Cozin M, Cremers S et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg.66(5), 839–847 (2008).
   PubMedGoogle Scholar
• Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br. J. Haematol.144(5), 667–676 (2009).
   PubMed Web of Science ®Google Scholar
• Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone41(3), 318–320 (2007).
   PubMed Web of Science ®Google Scholar
• Reid IR. Osteonecrosis of the jaw – who gets it, and why? Bone44(1), 4–10. (2009).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Vahtsevanos K. Increased risk for biphosphonate related osteonecrosis of the jaws in patients wearing overdentures could be attributable to impaired mucosal cell wound healing. J. Oral Maxillofac. Surg.67(6), 1355–1356 (2008).
   Google Scholar
• Thomson AB, Appleman S, Keelan M, Wallace JL. Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa. Dig. Dis. Sci.48(2), 308–314 (2003).
   PubMed Web of Science ®Google Scholar
• Amagase K, Hayashi S, Nishikawa K, Aihara E, Takeuchi K. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig. Dis. Sci.52(8), 1879–1889 (2007).
   PubMedGoogle Scholar
• de Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N. Engl. J. Med.335(14), 1016–1021 (1996).
   PubMed Web of Science ®Google Scholar
• Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med.360(1), 89–90 (2009).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J. Surg. Res.125(2), 189–212 (2005).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Triaridis S, Antoniades K. Effects of bisphosphonates on keratinocytes and fibroblasts may have a role in the development of osteonecrosis of the jaw. Bioscience Hypotheses2(3), 153–159 (2009).
   Google Scholar
• Idris AI, Rojas J, Greig IR, Van’t Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif. Tissue Int.82(3), 191–201 (2008).
   PubMed Web of Science ®Google Scholar
• Hays PL, Kawamura S, Deng XH et al. The role of macrophages in early healing of a tendon graft in a bone tunnel. J. Bone Joint Surg. Am.90(3), 565–579 (2008).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res.13(15 Pt 1), 4482–4486 (2007).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Morishige K, Sawada K et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun.354(2), 478–484 (2007).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann CH. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev. Anticancer Ther.4(6), 991–1005 (2004).
   PubMedGoogle Scholar
• von Knoch F, Jaquiery C, Kowalsky M et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials26(34), 6941–6949 (2005).
   PubMed Web of Science ®Google Scholar
• Pan B, To LB, Farrugia AN et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone34(1), 112–123 (2004).
   PubMed Web of Science ®Google Scholar
• Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K, Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K–Akt–NFκB pathway in osteosarcoma cells. Br. J. Pharmacol.146(5), 633–641 (2005).
   PubMed Web of Science ®Google Scholar
• Corso A, Ferretti E, Lunghi M et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer104(1), 118–125 (2005).
   PubMedGoogle Scholar
• Yu J, Chang SS, Suratwala S et al. Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). J. Orthop. Res.23(5), 1004–1012 (2005).
   PubMedGoogle Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg.63(11), 1567–1575 (2005).
   PubMed Web of Science ®Google Scholar
• Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis.14(3), 277–285 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez Font R, Martinez Garcia ML, Olmos Martinez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med. Oral Patol. Oral Cir. Bucal.13(5), E318–E324 (2008).
   Google Scholar
• Akintoye SO, Lam T, Shi S, Brahim J, Collins MT, Robey PG. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone38(6), 758–768 (2006).
   PubMed Web of Science ®Google Scholar
• Meran S, Thomas DW, Stephens P et al. Hyaluronan facilitates transforming growth factor-β1-mediated fibroblast proliferation. J. Biol. Chem.283(10), 6530–6545 (2008).
   PubMed Web of Science ®Google Scholar
• van Beurden HE, Snoek PA, Von den Hoff JW, Torensma R, Kuijpers-Jagtman AM. Fibroblast subpopulations in intra-oral wound healing. Wound Repair Regen.11(1), 55–63 (2003).
   PubMedGoogle Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg.62(5), 527–534 (2004).
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res.23(6), 826–836 (2008).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica91(7), 968–971 (2006).
   PubMed Web of Science ®Google Scholar
• Estilo CL, Van Poznak CH, Wiliams T et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist13(8), 911–920 (2008).
   PubMed Web of Science ®Google Scholar
• Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br. Dent. J.206(2), 93–98 (2009).
   PubMedGoogle Scholar
• Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum.32(2), 94–124 (2002).
   PubMed Web of Science ®Google Scholar
• Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol.45(6), e38 (2009).
   Google Scholar
• Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am. J. Med.121(6), 475–483 e473 (2008).
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest.27(2), 221–226 (2009).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Pervena A, Klouvas G et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology76(3), 209–211 (2009).
   PubMed Web of Science ®Google Scholar
• Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann. Oncol.19(12), 2091–2092 (2008).
   PubMed Web of Science ®Google Scholar
• Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J. Clin. Oncol.26(24), 4037–4038 (2008).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol.20(1), 117–120 (2009).
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. the experience of the National Cancer Institute of Milan. Ann. Oncol.20(1), 137–145 (2009).
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med.144(10), 753–761 (2006).
   PubMed Web of Science ®Google Scholar
• Wutzl A, Biedermann E, Wanschitz F et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck30(9), 1224–1230 (2008).
   PubMedGoogle Scholar
• Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J. Craniomaxillofac. Surg.33(6), 395–403 (2005).
   PubMed Web of Science ®Google Scholar
• Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer104(1), 83–93 (2005).
   PubMed Web of Science ®Google Scholar
• Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann. Oncol.17(8), 1197–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Coleman RE. The role of bone markers in metastatic bone disease. Cancer Treat. Rev.32(Suppl. 1), 1–2 (2006).
   PubMedGoogle Scholar
• Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. Br. J. Oral Maxillofac. Surg.67(5 Suppl. 1), 2–12 (2009).
   Google Scholar
• Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol. Oncol.26(4), 420–425 (2008).
   PubMed Web of Science ®Google Scholar
• Deal C. Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol.5(1), 20–27 (2009).
   PubMedGoogle Scholar
• Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr. Opin. Support Palliat. Care2(3), 197–203 (2008).
   PubMedGoogle Scholar
• Kyrgidis A, Triaridis S. Comment on: bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol.45(6), e38 (2009)
   Google Scholar
• Kyrgidis A, Andreadis C. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonates osteonecrosis of the jaw in breast cancer patient. Oncologist14, 101–102 (2009).
   PubMedGoogle Scholar
• Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N. Engl. J. Med.359(3), 316–317; author reply 317–318 (2008).
   PubMed Web of Science ®Google Scholar
• Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med.358(12), 1304–1306 (2008).
   PubMed Web of Science ®Google Scholar
• Lenart BA, Neviaser AS, Lyman S et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int. DOI 10.1007/s00198-008-0805-x (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Stephens R. Metal Fatigue in Engineering (Second edition). John Wiley & Sons, Inc, New York, NY, USA (2001).
   Google Scholar
• Wheeless CR. Wheeless’ Textbook of Orthopaedics. Van Der Bauwhede J, Sherry E (Eds). (1996)
   Google Scholar
• Kyrgidis A, Triaridis S. Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding ‘risks and benefits of bisphosphonates’. Br. J. Cancer100(4), 670 (2009).
   PubMedGoogle Scholar
• Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol.127(5), 998–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC, Leung KM. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol.37(3), 225–233 (2001).
   PubMed Web of Science ®Google Scholar
• Kim SG, Chae CH, Cho BO et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J. Oral Pathol. Med.35(1), 37–45 (2006).
   PubMedGoogle Scholar
• Poulsen RC, Wolber FM, Moughan PJ, Kruger MC. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat.85(1–2), 42–48 (2008).
   PubMed Web of Science ®Google Scholar
• Boswell BA, Lein PJ, Musil LS. Cross-talk between fibroblast growth factor and bone morphogenetic proteins regulates gap junction-mediated intercellular communication in lens cells. Mol. Biol. Cell19(6), 2631–2641 (2008).
   PubMedGoogle Scholar
• Kajiya H, Ito M, Ohshima H et al. RANK ligand expression in heat shock factor-2 deficient mouse bone marrow stromal/preosteoblast cells. J. Cell Biochem.97(6), 1362–1369 (2006).
   PubMedGoogle Scholar
• Barling PM, Lai AK, Nicholson LF. Distribution of EGF and its receptor in growing red deer antler. Cell Biol. Int.29(3), 229–236 (2005).
   PubMedGoogle Scholar
• Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen.16(5), 585–601 (2008).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Triaridis S, Vahtsevanos K. New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment. Hippokratia13(1), 64 (2009).
   PubMedGoogle Scholar